Britain to introduce framework for reducing animal testing in drug development
Britain's medicines regulator announced plans to introduce a framework by the end of 2026 to allow drug makers to seek review of data for drugs developed without animal testing. This initiative aims to reduce reliance on animal studies and aligns with a broader global push to limit such testing in drug development. The draft guidance from the United Kingdom's Medicines and Healthcare products Regulatory Agency encourages companies to adopt alternatives to animal testing, similar to efforts by the U.S. FDA.
Key Points
- Britain's medicines regulator will introduce a framework by end-2026 to allow drug makers to submit data for drugs developed without animal testing.
- The initiative aims to reduce reliance on animal studies in drug development.
- This move aligns with a broader global trend and efforts by regulatory bodies like the U.S. FDA to encourage alternatives.
- The framework will allow companies to seek a review of non-animal tested drugs before applying for approval.
Exam Facts
- Issuing body: United Kingdom's Medicines and Healthcare products Regulatory Agency.
- Framework to be introduced by end of 2026.
- U.S. FDA also issued similar draft guidance.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.